Manipulating the Interferon Signaling Pathway: Implications for HIV Infection
|
摘要
During human immunodeficiency virus(HIV) infection, type I interferon(IFN-I) signaling induces an antiviral state that includes the production of restriction factors that inhibit virus replication, thereby limiting the infection. As seen in other viral infections, type I IFN can also increase systemic immune activation which, in HIV disease, is one of the strongest predictors of disease progression to acquired immune deficiency syndrome(AIDS) and non-AIDS morbidity and mortality.Moreover, IFN-I is associated with CD4 T cell depletion and attenuation of antigen-specific T cell responses. Therefore,therapeutic manipulation of IFN-I signaling to improve HIV disease outcome is a source of much interest and debate in thefield. Recent studies have highlighted the importance of timing(acute vs. chronic infection) and have suggested that specific targeting of type I IFNs and their subtypes may help harness the beneficial roles of the IFN-I system while avoiding its deleterious activities.
During human immunodeficiency virus(HIV) infection, type I interferon(IFN-I) signaling induces an antiviral state that includes the production of restriction factors that inhibit virus replication, thereby limiting the infection. As seen in other viral infections, type I IFN can also increase systemic immune activation which, in HIV disease, is one of the strongest predictors of disease progression to acquired immune deficiency syndrome(AIDS) and non-AIDS morbidity and mortality.Moreover, IFN-I is associated with CD4 T cell depletion and attenuation of antigen-specific T cell responses. Therefore,therapeutic manipulation of IFN-I signaling to improve HIV disease outcome is a source of much interest and debate in thefield. Recent studies have highlighted the importance of timing(acute vs. chronic infection) and have suggested that specific targeting of type I IFNs and their subtypes may help harness the beneficial roles of the IFN-I system while avoiding its deleterious activities.
During human immunodeficiency virus(HIV) infection, type I interferon(IFN-I) signaling induces an antiviral state that includes the production of restriction factors that inhibit virus replication, thereby limiting the infection. As seen in other viral infections, type I IFN can also increase systemic immune activation which, in HIV disease, is one of the strongest predictors of disease progression to acquired immune deficiency syndrome(AIDS) and non-AIDS morbidity and mortality.Moreover, IFN-I is associated with CD4 T cell depletion and attenuation of antigen-specific T cell responses. Therefore,therapeutic manipulation of IFN-I signaling to improve HIV disease outcome is a source of much interest and debate in thefield. Recent studies have highlighted the importance of timing(acute vs. chronic infection) and have suggested that specific targeting of type I IFNs and their subtypes may help harness the beneficial roles of the IFN-I system while avoiding its deleterious activities.
引文
Abraham S,Choi JG,Ortega NM,Zhang J,Shankar P,Swamy NM(2016)Gene therapy with plasmids encoding IFN-beta or IFN-alpha14 confers long-term resistance to HIV-1 in humanized mice.Oncotarget 7:78412-78420
Bosinger SE,Utay NS(2015)Type I interferon:understanding its role in HIV pathogenesis and therapy.Curr HIV/AIDS Rep 12:41-53
Bosinger SE,Li Q,Gordon SN,Klatt NR,Duan L,Xu L,Francella N,Sidahmed A,Smith AJ,Cramer EM,Zeng M,Masopust D,Carlis JV,Ran L,Vanderford TH,Paiardini M,Isett RB,Baldwin DA,Else JG,Staprans SI,Silvestri G,Haase AT,Kelvin DJ(2009)Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys.J Clin Investig 119:3556-3572
Carnathan D,Lawson B,Yu J,Patel K,Billingsley JM,Tharp GK,Delmas OM,Dawoud R,Wilkinson P,Nicolette C,Cameron MJ,Sekaly RP,Bosinger SE,Silvestri G,Vanderford TH(2018)Reduced chronic lymphocyte activation following Interferonalpha blockade in the acute phase of SIV infection in rhesus macaques.J Virol.https://doi.org/10.1128/jvi.01760-17
Cheng L,Ma J,Li J,Li D,Li G,Li F,Zhang Q,Yu H,Yasui F,Ye C,Tsao LC,Hu Z,Su L,Zhang L(2017)Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.J Clin Investig 127:269-279
Davidson S,Crotta S,McCabe TM,Wack A(2014)Pathogenic potential of interferon alphabeta in acute influenza infection.Nat Commun 5:3864
Dunham RM,Vujkovic-Cvijin I,Yukl SA,Broadhurst MJ,Loke P,Albright RG,Wong JK,Lederman MM,Somsouk M,Hunt PW,Martin JN,Deeks SG,McCune JM(2014)Discordance between peripheral and colonic markers of inflammation during suppressive ART.J Acquir Immune Defic Syndr 65:133-141
El-Diwany R,Soliman M,Sugawara S,Breitwieser F,Skaist A,Coggiano C,Sangal N,Chattergoon M,Bailey JR,Siliciano RF,Blankson JN,Ray SC,Wheelan SJ,Thomas DL,Balagopal A(2018)CMPK2 and BCL-G are associated with type 1interferon-induced HIV restriction in humans.Sci Adv4:eaat0843
Fernandez S,Tanaskovic S,Helbig K,Rajasuriar R,Kramski M,Murray JM,Beard M,Purcell D,Lewin SR,Price P,French MA(2011)CD4?T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4?T cells.J Infect Dis204:1927-1935
Fletcher CV,Staskus K,Wietgrefe SW,Rothenberger M,Reilly C,Chipman JG,Beilman GJ,Khoruts A,Thorkelson A,Schmidt TE,Anderson J,Perkey K,Stevenson M,Perelson AS,Douek DC,Haase AT,Schacker TW(2014)Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.Proc Natl Acad Sci USA 111:2307-2312
Garcia-Sastre A,Biron CA(2006)Type 1 interferons and the virushost relationship:a lesson in detente.Science 312:879-882
Hardy GA,Sieg S,Rodriguez B,Anthony D,Asaad R,Jiang W,Mudd J,Schacker T,Funderburg NT,Pilch-Cooper HA,Debernardo R,Rabin RL,Lederman MM,Harding CV(2013)Interferon-alpha is the primary plasma type-I IFN in HIV-1infection and correlates with immune activation and disease markers.PLoS ONE 8:e56527
Harris LD,Tabb B,Sodora DL,Paiardini M,Klatt NR,Douek DC,Silvestri G,Muller-Trutwin M,Vasile-Pandrea I,Apetrei C,Hirsch V,Lifson J,Brenchley JM,Estes JD(2010)Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus(SIV)infection of natural hosts from pathogenic SIV infection of rhesus macaques.J Virol 84:7886-7891
Henrich TJ,Hatano H,Bacon O,Hogan LE,Rutishauser R,Hill A,Kearney MF,Anderson EM,Buchbinder SP,Cohen SE,AbdelMohsen M,Pohlmeyer CW,Fromentin R,Hoh R,Liu AY,McCune JM,Spindler J,Metcalf-Pate K,Hobbs KS,Thanh C,Gibson EA,Kuritzkes DR,Siliciano RF,Price RW,Richman DD,Chomont N,Siliciano JD,Mellors JW,Yukl SA,Blankson JN,Liegler T,Deeks SG(2017)HIV-1 persistence following extremely early initiation of antiretroviral therapy(ART)during acute HIV-1 infection:an observational study.PLoS Med14:e1002417
Huang KJ,Su IJ,Theron M,Wu YC,Lai SK,Liu CC,Lei HY(2005)An interferon-gamma-related cytokine storm in SARS patients.J Med Virol 75:185-194
Hunt PW(2012)HIV and inflammation:mechanisms and consequences.Curr HIV/AIDS Rep 9:139-147
Jacquelin B,Mayau V,Targat B,Liovat AS,Kunkel D,Petitjean G,Dillies MA,Roques P,Butor C,Silvestri G,Giavedoni LD,Lebon P,Barre-Sinoussi F,Benecke A,Muller-Trutwin MC(2009)Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.J Clin Investig 119:3544-3555
Johns TG,Kerry JA,Veitch BA,Mackay IR,Tutton PJ,Tymms MJ,Cheetham BF,Hertzog PJ,Linnane AW(1990)Pharmacokinetics,tissue distribution,and cell localization of[35S]methioninelabeled recombinant human and murine alpha interferons in mice.Cancer Res 50:4718-4723
Lavender KJ,Gibbert K,Peterson KE,Van Dis E,Francois S,Woods T,Messer RJ,Gawanbacht A,Muller JA,Munch J,Phillips K,Race B,Harper MS,Guo K,Lee EJ,Trilling M,Hengel H,Piehler J,Verheyen J,Wilson CC,Santiago ML,Hasenkrug KJ,Dittmer U(2016)Interferon alpha subtype-specific suppression of HIV-1 infection in vivo.J Virol 90:6001-6013
Liu SY,Sanchez DJ,Aliyari R,Lu S,Cheng G(2012)Systematic identification of type I and type II interferon-induced antiviral factors.Proc Natl Acad Sci USA 109:4239-4244
Lorenzo-Redondo R,Fryer HR,Bedford T,Kim EY,Archer J,Pond SLK,Chung YS,Penugonda S,Chipman J,Fletcher CV,Schacker TW,Malim MH,Rambaut A,Haase AT,McLean AR,Wolinsky SM(2016)Persistent HIV-1 replication maintains the tissue reservoir during therapy.Nature 530:51-56
Marshall HD,Urban SL,Welsh RM(2011)Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon.J Virol 85:5929-5939
Massanella M,Tural C,Papagno L,Garcia E,Jou A,Bofill M,Autran B,Clotet B,Blanco J(2010)Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.Antivir Ther 15:333-342
Muller U,Steinhoff U,Reis LF,Hemmi S,Pavlovic J,Zinkernagel RM,Aguet M(1994)Functional role of type I and type IIinterferons in antiviral defense.Science 264:1918-1921
Ng CT,Sullivan BM,Teijaro JR,Lee AM,Welch M,Rice S,Sheehan KC,Schreiber RD,Oldstone MB(2015)Blockade of interferon beta,but not interferon alpha,signaling controls persistent viral infection.Cell Host Microbe 17:653-661
Nganou-Makamdop K,Billingsley JM,Yaffe Z,O'Connor G,Tharp GK,Ransier A,Laboune F,Matus-Nicodemos R,Lerner A,Gharu L,Robertson JM,Ford ML,Schlapschy M,Kuhn N,Lensch A,Lifson J,Nason M,Skerra A,Schreiber G,Bosinger SE,Douek DC(2018)Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication.PLoS Pathog 14:e1007246
Palesch D,Bosinger SE,Mavigner M,Billingsley JM,Mattingly C,Carnathan D,Paiardini M,Chahroudi A,Vanderford T,Silvestri G(2018)Short-term pIFN-alpha2a treatment does not significantly reduce the viral reservoir of SIV-infected,ART-treated rhesus macaques.J Virol.https://doi.org/10.1128/jvi.00279-18
Pestka S,Krause CD,Walter MR(2004)Interferons,interferon-like cytokines,and their receptors.Immunol Rev 202:8-32
Rothenberger MK,Keele BF,Wietgrefe SW,Fletcher CV,Beilman GJ,Chipman JG,Khoruts A,Estes JD,Anderson J,Callisto SP,Schmidt TE,Thorkelson A,Reilly C,Perkey K,Reimann TG,Utay NS,Nganou Makamdop K,Stevenson M,Douek DC,Haase AT,Schacker TW(2015)Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.Proc Natl Acad Sci USA 112:E1126-E1134
Sandler NG,Bosinger SE,Estes JD,Zhu RT,Tharp GK,Boritz E,Levin D,Wijeyesinghe S,Makamdop KN,del Prete GQ,Hill BJ,Timmer JK,Reiss E,Yarden G,Darko S,Contijoch E,Todd JP,Silvestri G,Nason M,Norgren RB Jr,Keele BF,Rao S,Langer JA,Lifson JD,Schreiber G,Douek DC(2014)Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression.Nature 511:601-605
Schoggins JW,Wilson SJ,Panis M,Murphy MY,Jones CT,Bieniasz P,Rice CM(2011)A diverse range of gene products are effectors of the type I interferon antiviral response.Nature472:481-485
Sereti I,Krebs SJ,Phanuphak N,Fletcher JL,Slike B,Pinyakorn S,O'Connell RJ,Rupert A,Chomont N,Valcour V,Kim JH,Robb ML,Michael NL,Douek DC,Ananworanich J,Utay NS,Rv254/Search RS,teams Sp(2017)Persistent,Albeit reduced,chronic inflammation in persons starting antiretroviral therapy in acute HIV infection.Clin Infect Dis 64:124-131
Soper A,Kimura I,Nagaoka S,Konno Y,Yamamoto K,Koyanagi Y,Sato K(2017)Type I interferon responses by HIV-1 infection:association with disease progression and control.Front Immunol8:1823
Stacey AR,Norris PJ,Qin L,Haygreen EA,Taylor E,Heitman J,Lebedeva M,DeCamp A,Li D,Grove D,Self SG,Borrow P(2009)Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1infection,in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.J Virol 83:3719-3733
Teijaro JR,Walsh KB,Cahalan S,Fremgen DM,Roberts E,Scott F,Martinborough E,Peach R,Oldstone MB,Rosen H(2011)Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection.Cell 146:980-991
Teijaro JR,Ng C,Lee AM,Sullivan BM,Sheehan KC,Welch M,Schreiber RD,de la Torre JC,Oldstone MB(2013)Persistent LCMV infection is controlled by blockade of type I interferon signaling.Science 340:207-211
Teijaro JR,Studer S,Leaf N,Kiosses WB,Nguyen N,Matsuki K,Negishi H,Taniguchi T,Oldstone MB,Rosen H(2016)S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-alpha autoamplification.Proc Natl Acad Sci USA 113:1351-1356
Utay NS,Douek DC(2016)Interferons and HIV infection:the good,the bad,and the ugly.Pathog Immun 1:107-116
Veazey RS,Pilch-Cooper HA,Hope TJ,Alter G,Carias AM,Sips M,Wang X,Rodriguez B,Sieg SF,Reich A,Wilkinson P,Cameron MJ,Lederman MM(2016)Prevention of SHIV transmission by topical IFN-beta treatment.Mucosal Immunol 9:1528-1536
Walsh KB,Teijaro JR,Wilker PR,Jatzek A,Fremgen DM,Das SC,Watanabe T,Hatta M,Shinya K,Suresh M,Kawaoka Y,Rosen H,Oldstone MB(2011)Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.Proc Natl Acad Sci USA 108:12018-12023
Wilson EB,Yamada DH,Elsaesser H,Herskovitz J,Deng J,Cheng G,Aronow BJ,Karp CL,Brooks DG(2013)Blockade of chronic type I interferon signaling to control persistent LCMV infection.Science 340:202-207
Yan N,Chen ZJ(2012)Intrinsic antiviral immunity.Nat Immunol13:214-222
Zhen A,Rezek V,Youn C,Lam B,Chang N,Rick J,Carrillo M,Martin H,Kasparian S,Syed P,Rice N,Brooks DG,Kitchen SG(2017)Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.J Clin Investig127:260-268
Bosinger SE,Utay NS(2015)Type I interferon:understanding its role in HIV pathogenesis and therapy.Curr HIV/AIDS Rep 12:41-53
Bosinger SE,Li Q,Gordon SN,Klatt NR,Duan L,Xu L,Francella N,Sidahmed A,Smith AJ,Cramer EM,Zeng M,Masopust D,Carlis JV,Ran L,Vanderford TH,Paiardini M,Isett RB,Baldwin DA,Else JG,Staprans SI,Silvestri G,Haase AT,Kelvin DJ(2009)Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys.J Clin Investig 119:3556-3572
Carnathan D,Lawson B,Yu J,Patel K,Billingsley JM,Tharp GK,Delmas OM,Dawoud R,Wilkinson P,Nicolette C,Cameron MJ,Sekaly RP,Bosinger SE,Silvestri G,Vanderford TH(2018)Reduced chronic lymphocyte activation following Interferonalpha blockade in the acute phase of SIV infection in rhesus macaques.J Virol.https://doi.org/10.1128/jvi.01760-17
Cheng L,Ma J,Li J,Li D,Li G,Li F,Zhang Q,Yu H,Yasui F,Ye C,Tsao LC,Hu Z,Su L,Zhang L(2017)Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.J Clin Investig 127:269-279
Davidson S,Crotta S,McCabe TM,Wack A(2014)Pathogenic potential of interferon alphabeta in acute influenza infection.Nat Commun 5:3864
Dunham RM,Vujkovic-Cvijin I,Yukl SA,Broadhurst MJ,Loke P,Albright RG,Wong JK,Lederman MM,Somsouk M,Hunt PW,Martin JN,Deeks SG,McCune JM(2014)Discordance between peripheral and colonic markers of inflammation during suppressive ART.J Acquir Immune Defic Syndr 65:133-141
El-Diwany R,Soliman M,Sugawara S,Breitwieser F,Skaist A,Coggiano C,Sangal N,Chattergoon M,Bailey JR,Siliciano RF,Blankson JN,Ray SC,Wheelan SJ,Thomas DL,Balagopal A(2018)CMPK2 and BCL-G are associated with type 1interferon-induced HIV restriction in humans.Sci Adv4:eaat0843
Fernandez S,Tanaskovic S,Helbig K,Rajasuriar R,Kramski M,Murray JM,Beard M,Purcell D,Lewin SR,Price P,French MA(2011)CD4?T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4?T cells.J Infect Dis204:1927-1935
Fletcher CV,Staskus K,Wietgrefe SW,Rothenberger M,Reilly C,Chipman JG,Beilman GJ,Khoruts A,Thorkelson A,Schmidt TE,Anderson J,Perkey K,Stevenson M,Perelson AS,Douek DC,Haase AT,Schacker TW(2014)Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.Proc Natl Acad Sci USA 111:2307-2312
Garcia-Sastre A,Biron CA(2006)Type 1 interferons and the virushost relationship:a lesson in detente.Science 312:879-882
Hardy GA,Sieg S,Rodriguez B,Anthony D,Asaad R,Jiang W,Mudd J,Schacker T,Funderburg NT,Pilch-Cooper HA,Debernardo R,Rabin RL,Lederman MM,Harding CV(2013)Interferon-alpha is the primary plasma type-I IFN in HIV-1infection and correlates with immune activation and disease markers.PLoS ONE 8:e56527
Harris LD,Tabb B,Sodora DL,Paiardini M,Klatt NR,Douek DC,Silvestri G,Muller-Trutwin M,Vasile-Pandrea I,Apetrei C,Hirsch V,Lifson J,Brenchley JM,Estes JD(2010)Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus(SIV)infection of natural hosts from pathogenic SIV infection of rhesus macaques.J Virol 84:7886-7891
Henrich TJ,Hatano H,Bacon O,Hogan LE,Rutishauser R,Hill A,Kearney MF,Anderson EM,Buchbinder SP,Cohen SE,AbdelMohsen M,Pohlmeyer CW,Fromentin R,Hoh R,Liu AY,McCune JM,Spindler J,Metcalf-Pate K,Hobbs KS,Thanh C,Gibson EA,Kuritzkes DR,Siliciano RF,Price RW,Richman DD,Chomont N,Siliciano JD,Mellors JW,Yukl SA,Blankson JN,Liegler T,Deeks SG(2017)HIV-1 persistence following extremely early initiation of antiretroviral therapy(ART)during acute HIV-1 infection:an observational study.PLoS Med14:e1002417
Huang KJ,Su IJ,Theron M,Wu YC,Lai SK,Liu CC,Lei HY(2005)An interferon-gamma-related cytokine storm in SARS patients.J Med Virol 75:185-194
Hunt PW(2012)HIV and inflammation:mechanisms and consequences.Curr HIV/AIDS Rep 9:139-147
Jacquelin B,Mayau V,Targat B,Liovat AS,Kunkel D,Petitjean G,Dillies MA,Roques P,Butor C,Silvestri G,Giavedoni LD,Lebon P,Barre-Sinoussi F,Benecke A,Muller-Trutwin MC(2009)Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.J Clin Investig 119:3544-3555
Johns TG,Kerry JA,Veitch BA,Mackay IR,Tutton PJ,Tymms MJ,Cheetham BF,Hertzog PJ,Linnane AW(1990)Pharmacokinetics,tissue distribution,and cell localization of[35S]methioninelabeled recombinant human and murine alpha interferons in mice.Cancer Res 50:4718-4723
Lavender KJ,Gibbert K,Peterson KE,Van Dis E,Francois S,Woods T,Messer RJ,Gawanbacht A,Muller JA,Munch J,Phillips K,Race B,Harper MS,Guo K,Lee EJ,Trilling M,Hengel H,Piehler J,Verheyen J,Wilson CC,Santiago ML,Hasenkrug KJ,Dittmer U(2016)Interferon alpha subtype-specific suppression of HIV-1 infection in vivo.J Virol 90:6001-6013
Liu SY,Sanchez DJ,Aliyari R,Lu S,Cheng G(2012)Systematic identification of type I and type II interferon-induced antiviral factors.Proc Natl Acad Sci USA 109:4239-4244
Lorenzo-Redondo R,Fryer HR,Bedford T,Kim EY,Archer J,Pond SLK,Chung YS,Penugonda S,Chipman J,Fletcher CV,Schacker TW,Malim MH,Rambaut A,Haase AT,McLean AR,Wolinsky SM(2016)Persistent HIV-1 replication maintains the tissue reservoir during therapy.Nature 530:51-56
Marshall HD,Urban SL,Welsh RM(2011)Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon.J Virol 85:5929-5939
Massanella M,Tural C,Papagno L,Garcia E,Jou A,Bofill M,Autran B,Clotet B,Blanco J(2010)Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.Antivir Ther 15:333-342
Muller U,Steinhoff U,Reis LF,Hemmi S,Pavlovic J,Zinkernagel RM,Aguet M(1994)Functional role of type I and type IIinterferons in antiviral defense.Science 264:1918-1921
Ng CT,Sullivan BM,Teijaro JR,Lee AM,Welch M,Rice S,Sheehan KC,Schreiber RD,Oldstone MB(2015)Blockade of interferon beta,but not interferon alpha,signaling controls persistent viral infection.Cell Host Microbe 17:653-661
Nganou-Makamdop K,Billingsley JM,Yaffe Z,O'Connor G,Tharp GK,Ransier A,Laboune F,Matus-Nicodemos R,Lerner A,Gharu L,Robertson JM,Ford ML,Schlapschy M,Kuhn N,Lensch A,Lifson J,Nason M,Skerra A,Schreiber G,Bosinger SE,Douek DC(2018)Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication.PLoS Pathog 14:e1007246
Palesch D,Bosinger SE,Mavigner M,Billingsley JM,Mattingly C,Carnathan D,Paiardini M,Chahroudi A,Vanderford T,Silvestri G(2018)Short-term pIFN-alpha2a treatment does not significantly reduce the viral reservoir of SIV-infected,ART-treated rhesus macaques.J Virol.https://doi.org/10.1128/jvi.00279-18
Pestka S,Krause CD,Walter MR(2004)Interferons,interferon-like cytokines,and their receptors.Immunol Rev 202:8-32
Rothenberger MK,Keele BF,Wietgrefe SW,Fletcher CV,Beilman GJ,Chipman JG,Khoruts A,Estes JD,Anderson J,Callisto SP,Schmidt TE,Thorkelson A,Reilly C,Perkey K,Reimann TG,Utay NS,Nganou Makamdop K,Stevenson M,Douek DC,Haase AT,Schacker TW(2015)Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.Proc Natl Acad Sci USA 112:E1126-E1134
Sandler NG,Bosinger SE,Estes JD,Zhu RT,Tharp GK,Boritz E,Levin D,Wijeyesinghe S,Makamdop KN,del Prete GQ,Hill BJ,Timmer JK,Reiss E,Yarden G,Darko S,Contijoch E,Todd JP,Silvestri G,Nason M,Norgren RB Jr,Keele BF,Rao S,Langer JA,Lifson JD,Schreiber G,Douek DC(2014)Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression.Nature 511:601-605
Schoggins JW,Wilson SJ,Panis M,Murphy MY,Jones CT,Bieniasz P,Rice CM(2011)A diverse range of gene products are effectors of the type I interferon antiviral response.Nature472:481-485
Sereti I,Krebs SJ,Phanuphak N,Fletcher JL,Slike B,Pinyakorn S,O'Connell RJ,Rupert A,Chomont N,Valcour V,Kim JH,Robb ML,Michael NL,Douek DC,Ananworanich J,Utay NS,Rv254/Search RS,teams Sp(2017)Persistent,Albeit reduced,chronic inflammation in persons starting antiretroviral therapy in acute HIV infection.Clin Infect Dis 64:124-131
Soper A,Kimura I,Nagaoka S,Konno Y,Yamamoto K,Koyanagi Y,Sato K(2017)Type I interferon responses by HIV-1 infection:association with disease progression and control.Front Immunol8:1823
Stacey AR,Norris PJ,Qin L,Haygreen EA,Taylor E,Heitman J,Lebedeva M,DeCamp A,Li D,Grove D,Self SG,Borrow P(2009)Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1infection,in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.J Virol 83:3719-3733
Teijaro JR,Walsh KB,Cahalan S,Fremgen DM,Roberts E,Scott F,Martinborough E,Peach R,Oldstone MB,Rosen H(2011)Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection.Cell 146:980-991
Teijaro JR,Ng C,Lee AM,Sullivan BM,Sheehan KC,Welch M,Schreiber RD,de la Torre JC,Oldstone MB(2013)Persistent LCMV infection is controlled by blockade of type I interferon signaling.Science 340:207-211
Teijaro JR,Studer S,Leaf N,Kiosses WB,Nguyen N,Matsuki K,Negishi H,Taniguchi T,Oldstone MB,Rosen H(2016)S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-alpha autoamplification.Proc Natl Acad Sci USA 113:1351-1356
Utay NS,Douek DC(2016)Interferons and HIV infection:the good,the bad,and the ugly.Pathog Immun 1:107-116
Veazey RS,Pilch-Cooper HA,Hope TJ,Alter G,Carias AM,Sips M,Wang X,Rodriguez B,Sieg SF,Reich A,Wilkinson P,Cameron MJ,Lederman MM(2016)Prevention of SHIV transmission by topical IFN-beta treatment.Mucosal Immunol 9:1528-1536
Walsh KB,Teijaro JR,Wilker PR,Jatzek A,Fremgen DM,Das SC,Watanabe T,Hatta M,Shinya K,Suresh M,Kawaoka Y,Rosen H,Oldstone MB(2011)Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.Proc Natl Acad Sci USA 108:12018-12023
Wilson EB,Yamada DH,Elsaesser H,Herskovitz J,Deng J,Cheng G,Aronow BJ,Karp CL,Brooks DG(2013)Blockade of chronic type I interferon signaling to control persistent LCMV infection.Science 340:202-207
Yan N,Chen ZJ(2012)Intrinsic antiviral immunity.Nat Immunol13:214-222
Zhen A,Rezek V,Youn C,Lam B,Chang N,Rick J,Carrillo M,Martin H,Kasparian S,Syed P,Rice N,Brooks DG,Kitchen SG(2017)Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.J Clin Investig127:260-268